-
![3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives](/abs-image/US/2015/04/07/US08999981B2/abs.jpg.150x150.jpg)
1.发明授权3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives 有权3-氨基 - 吡咯并[3,4-C]吡唑-5（1H，4H，6H）甲醛衍生物公开(公告)号：US08999981B2
公开(公告)日：2015-04-07
申请号：US13345528
申请日：2012-01-06
Applicant: Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
Inventor： Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
IPC: A61K31/5377 , A61K31/495 , A61K31/499 , A61K31/497 , C07D413/14 , C07D237/02 , C07D239/02 , C07D241/02 , C07D241/36 , C07D239/70 , C07D403/14 , C07D401/14 , C07D487/04
CPC classification number: C07D487/04
Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
Abstract translation: 本发明涉及式（I）的化合物和药学上可接受的盐：其中X，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8如上所定义。 本发明还涉及包含该化合物和药学上可接受的盐的药物组合物以及治疗糖尿病及其并发症（特别是糖尿病性视网膜病变，肾病或神经病变），癌症，缺血，炎症，中枢神经系统疾病，心血管疾病， 阿尔茨海默病和皮肤病疾病，病毒性疾病，炎症性疾病或肝脏是靶器官的疾病。
-
![NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES](/abs-image/US/2010/09/30/US20100249128A1/abs.jpg.150x150.jpg)
2.发明申请NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES 有权新的3-氨基吡咯并[3,4-C]吡唑-5（1H，4H，6H）二氢苯并噻吩衍生物公开(公告)号：US20100249128A1
公开(公告)日：2010-09-30
申请号：US12532051
申请日：2008-04-10
Applicant: Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
Inventor： Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
IPC: A61K31/4985 , C07D487/04 , A61K31/499 , A61K31/496 , C07D471/04 , A61K31/506 , A61K31/519 , A61K31/5377 , A61P3/10 , A61P9/10 , A61P9/00 , A61P17/00 , A61P25/28 , A61P35/00 , A61P29/00 , A61P31/12 , A61P1/16 , A61P25/00
CPC classification number: C07D487/04
Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
Abstract translation: 本发明涉及式（I）的化合物和药学上可接受的盐：其中X，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8如上所定义。 本发明还涉及包含该化合物和药学上可接受的盐的药物组合物以及治疗糖尿病及其并发症（特别是糖尿病性视网膜病变，肾病或神经病变），癌症，缺血，炎症，中枢神经系统疾病，心血管疾病， 阿尔茨海默病和皮肤病疾病，病毒性疾病，炎症性疾病或肝脏是靶器官的疾病。
-
公开(公告)号：US08106197B2
公开(公告)日：2012-01-31
申请号：US11598765
申请日：2006-11-14
Applicant: Jingrong Jean Cui , Dilip Bhumralkar , Iriny Botrous , Ji Yu Chu , Lee A. Funk , Cathleen Elizabeth Hanau , G. Davis Harris , Lei Jia , Joanne Johnson , Stephen A. Kolodziej , Pei-Pei Kung , Xiaoyuan (Sharon) Li , Jason (Qishen) Lin , Jerry Jialun Meng , Mitchell David Nambu , Christopher G. Nelson , Mason Alan Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
Inventor： Jingrong Jean Cui , Dilip Bhumralkar , Iriny Botrous , Ji Yu Chu , Lee A. Funk , Cathleen Elizabeth Hanau , G. Davis Harris , Lei Jia , Joanne Johnson , Stephen A. Kolodziej , Pei-Pei Kung , Xiaoyuan (Sharon) Li , Jason (Qishen) Lin , Jerry Jialun Meng , Mitchell David Nambu , Christopher G. Nelson , Mason Alan Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
IPC: C07D241/02
CPC classification number: C07D213/73 , A61K45/06 , C07D401/12 , C07D413/12
Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
Abstract translation: 提供式（1）的氨基吡啶和氨基吡嗪化合物，包括这些化合物的组合物及其使用方法。 优选的式1化合物具有作为蛋白激酶抑制剂的活性，包括作为c-MET的抑制剂。
-
公开(公告)号：US20070072874A1
公开(公告)日：2007-03-29
申请号：US11598765
申请日：2006-11-14
Applicant: Jingrong Cui , Dilip Bhumralkar , Iriny Botrous , Ji Chu , Lee Funk , Cathleen Hanau , G. Harris , Lei Jia , Joanne Johnson , Stephen Kolodziej , Pei-Pei Kung , Xiaoyuan Li , Jason Lin , Jerry Meng , Mitchell Nambu , Christopher Nelson , Mason Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
Inventor： Jingrong Cui , Dilip Bhumralkar , Iriny Botrous , Ji Chu , Lee Funk , Cathleen Hanau , G. Harris , Lei Jia , Joanne Johnson , Stephen Kolodziej , Pei-Pei Kung , Xiaoyuan Li , Jason Lin , Jerry Meng , Mitchell Nambu , Christopher Nelson , Mason Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
IPC: A61K31/4965 , A61K31/497 , A61K31/4439 , A61K31/4412 , C07D403/02
CPC classification number: C07D213/73 , A61K45/06 , C07D401/12 , C07D413/12
Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
Abstract translation: 提供式（
-
![3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives](/abs-image/US/2012/02/14/US08114871B2/abs.jpg.150x150.jpg)
5.发明授权3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives 有权3-氨基 - 吡咯并[3,4-C]吡唑-5（1H，4H，6H）甲醛衍生物公开(公告)号：US08114871B2
公开(公告)日：2012-02-14
申请号：US12532051
申请日：2008-04-10
Applicant: Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
Inventor： Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
IPC: A61K31/535 , A61K31/495 , A61K31/497 , A61K31/4965 , C07D413/14 , C07D237/00 , C07D239/00 , C07D403/14 , C07D241/36 , C07D401/14
CPC classification number: C07D487/04
Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
Abstract translation: 本发明涉及式（I）的化合物和药学上可接受的盐：其中X，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8如上所定义。 本发明还涉及包含该化合物和药学上可接受的盐的药物组合物以及治疗糖尿病及其并发症（特别是糖尿病性视网膜病变，肾病或神经病变），癌症，缺血，炎症，中枢神经系统疾病，心血管疾病， 阿尔茨海默病和皮肤病疾病，病毒性疾病，炎症性疾病或肝脏是靶器官的疾病。
-
Patent Agency Ranking
公开(公告)号：US07230098B2
公开(公告)日：2007-06-12
申请号：US10786610
申请日：2004-02-26
Applicant: Jingrong Jean Cui , Dilip Bhumralkar , Iriny Botrous , Ji Yu Chu , Lee A. Funk , Cathleen Elizabeth Hanau , G. Davis Harris , Lei Jia , Joanne Johnson , Stephen A. Kolodziej , Pei-Pei Kung , Xiaoyuan (Sharon) Li , Jason (Qishen) Lin , Jerry Jialun Meng , Mitchell David Nambu , Christopher G. Nelson , Mason Alan Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
Inventor： Jingrong Jean Cui , Dilip Bhumralkar , Iriny Botrous , Ji Yu Chu , Lee A. Funk , Cathleen Elizabeth Hanau , G. Davis Harris , Lei Jia , Joanne Johnson , Stephen A. Kolodziej , Pei-Pei Kung , Xiaoyuan (Sharon) Li , Jason (Qishen) Lin , Jerry Jialun Meng , Mitchell David Nambu , Christopher G. Nelson , Mason Alan Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
IPC: C07D417/00 , C07D413/00 , C07D401/00 , C07D211/68 , C07D211/72
CPC classification number: C07D213/73 , A61K45/06 , C07D401/12 , C07D413/12
Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET
Abstract translation: 提供式（1）的氨基吡啶和氨基吡嗪化合物，包括这些化合物的组合物及其使用方法。 优选的式1化合物具有作为蛋白激酶抑制剂的活性，包括作为c-MET的抑制剂
-
公开(公告)号：US20050107391A1
公开(公告)日：2005-05-19
申请号：US10875507
申请日：2004-06-25
Applicant: Jingrong Cui , Iriny Botrous
Inventor： Jingrong Cui , Iriny Botrous
IPC: C07D471/04 , C07D487/04 , C07D487/02 , A61K31/4184 , A61K31/4192 , A61K31/4745 , A61K31/498 , C07D471/02
CPC classification number: C07D471/04 , C07D487/04
Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.
Abstract translation: 本发明涉及式（I） - （IV）的化合物，其中R 1 -R 6，R 11 -R 本文定义X和Y以及它们的药学上可接受的盐。 这些化合物调节c-Met的活性，因此预期可用于预防和治疗c-Met相关疾病如癌症。
-
![NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES](/abs-image/US/2012/05/03/US20120108588A1/abs.jpg.150x150.jpg)
8.发明申请NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES 审中-公开新的3-氨基吡咯并[3,4-C]吡唑-5（1H，4H，6H）二氢苯并噻吩衍生物公开(公告)号：US20120108588A1
公开(公告)日：2012-05-03
申请号：US13345528
申请日：2012-01-06
Applicant: Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
Inventor： Iriny Botrous , Yufeng Hong , Hui Li , Kevin Kun-Chin Liu , Seiji Nukui , Min Teng , Eileen Valenzuela Tompkins , Chunfeng Yin
IPC: A61K31/5377 , A61K31/4985 , A61K31/499 , A61K31/496 , A61K31/506 , A61P3/10 , A61P35/00 , A61P9/10 , A61P29/00 , A61P25/00 , A61P9/00 , A61P25/28 , A61P17/00 , A61P31/12 , A61P1/16 , C07D487/04
CPC classification number: C07D487/04
Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
Abstract translation: 本发明涉及式（I）的化合物和药学上可接受的盐：其中X，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8如上所定义。 本发明还涉及包含该化合物和药学上可接受的盐的药物组合物以及治疗糖尿病及其并发症（特别是糖尿病性视网膜病变，肾病或神经病变），癌症，缺血，炎症，中枢神经系统疾病，心血管疾病， 阿尔茨海默病和皮肤病疾病，病毒性疾病，炎症性疾病或肝脏是靶器官的疾病。
-
公开(公告)号：US07250417B2
公开(公告)日：2007-07-31
申请号：US10875507
申请日：2004-06-25
Applicant: Jingrong Cui , Iriny Botrous
Inventor： Jingrong Cui , Iriny Botrous
IPC: A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , C07D47/00
CPC classification number: C07D471/04 , C07D487/04
Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer
Abstract translation: 本发明涉及式（I） - （IV）的化合物，其中R 1 -R 6，R 11 -R 本文定义X和Y以及它们的药学上可接受的盐。 这些化合物调节c-Met的活性，因此预期可用于预防和治疗c-Met相关疾病如癌症
-
公开(公告)号：US20050009840A1
公开(公告)日：2005-01-13
申请号：US10786610
申请日：2004-02-26
Applicant: Jingrong Cui , Dilip Bhumralkar , Iriny Botrous , Ji Chu , Lee Funk , Cathleen Hanau , G. Harris , Lei Jia , Joanne Johnson , Stephen Kolodziej , Pei-Pei Kung , Xiaoyuan Li , Jason Lin , Jerry Meng , Mitchell Nambu , Christopher Nelson , Mason Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
Inventor： Jingrong Cui , Dilip Bhumralkar , Iriny Botrous , Ji Chu , Lee Funk , Cathleen Hanau , G. Harris , Lei Jia , Joanne Johnson , Stephen Kolodziej , Pei-Pei Kung , Xiaoyuan Li , Jason Lin , Jerry Meng , Mitchell Nambu , Christopher Nelson , Mason Pairish , Hong Shen , Michelle Tran-Dube , Allison Walter , Fang-Jie Zhang , Jennifer Zhang
IPC: A61K20060101 , A61K31/44 , A61K31/496 , A61K31/4965 , A61K31/497 , C07D20060101 , C07D211/72 , C07D213/73 , C07D401/00 , C07D401/12 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D413/12 , C07D417/00 , C07D419/00 , C07
CPC classification number: C07D213/73 , A61K45/06 , C07D401/12 , C07D413/12
Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.
Abstract translation: 提供式（1）的氨基吡啶和氨基吡嗪化合物，包括这些化合物的组合物及其使用方法。 优选的式1化合物具有作为蛋白激酶抑制剂的活性，包括作为c-MET的抑制剂。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.03 seconds)
